Why the study?
Diabetic nephropathy is traditionally diagnosed using ACR and eGFR, but newer biomarkers may offer better prediction of renal dysfunction in diabetic individuals without hypertension.
Do newer urinary biomarkers offer better prediction of early-stage renal disease progression compared to traditional biomarkers in diabetic individuals without concurrent hypertension?
Do newer urinary biomarkers offer better prediction of early-stage renal disease progression compared to traditional biomarkers in diabetic individuals without concurrent hypertension?
Newer urinary biomarkers such as cystatin C, NGAL, IL-18, and angiotensinogen may offer better prediction of renal dysfunction in diabetic individuals without hypertension.
May aid early renal risk stratification in normotensive diabetes; hypothesis-generating and requires prospective validation.
Background: Diabetic nephropathy (DN) is traditionally diagnosed based on urinary albumin-to-creatinine ratio (ACR) and estimated glomerular filtration rate (eGFR). Newer biomarkers, such as urinary cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), interleukin (IL)-18, and angiotensinogen, may offer better prediction of renal dysfunction in diabetes without hypertension.
No takes yet. Share an insight, caveat, or question.
Mahapatra et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: